Table 4 Selenium supplementation studies in patients who underwent radiotherapy
From: Updates on clinical studies of selenium supplementation in radiotherapy
Study no. | Reference | Type of cancer/disease | Type of study | Form of Se used for supplementation | Dose (μg) | Administration | Items observed/measured | Result |
|---|---|---|---|---|---|---|---|---|
11 | Pakdaman, [27] | Brain tumor | Not mentioned | Sodium selenite | 1000/day (4–8 weeks) | Infusion (during radiotherapy) | Mineral elements, Se and other blood parameters (AST, ALT, γ-GTP, ESR) | A significant diminution of symptoms of intracranial pressure was achieved in 76% of patients. |
12 | Kiremidjian-Schumacher et al. [28] | Head and neck cancer | Randomized double-blind placebo-controlled study | Sodium selenite | 200/day (8Â weeks) | Oral (during radiotherapy) | Se in plasma, CTL, MLR, PHA | Significantly enhanced cell-mediated immune responsiveness |
13 | Micke et al. [29] | Secondary Lymphedema | Not mentioned | Sodium selenite | 500/day (4–6 weeks) | Oral (4 or10 months after radiotherapy) | Foldi and Miller scoring and quality of life | Foldi and Miller score: more than 78% showed an improvement of one stage or more |
14 | Elango et al. [30] | Oral cancer | Not mentioned | Sodium selenite | 400/day (6Â months) | Oral (during radiotherapy) | Plasma Se, enzymatic (GPx and others) and non-enzymatic antioxidants | Supplementation increased the enzymatic and non enzymatic defense systems |
15 | Muecke et al. [31] | Cervical cancer (n = 11); Uterin cancer (n = 70) | Multicenter, phase 3 trial | Sodium selenite | 500 or 300/day | Oral (during radiotherapy) | Whole blood Se | Statistically significant in reducing the number of episode and severity of RT-induced diarrhea |
16 | Buntzel et al. [32] | Head and neck (n = 39) | Randomized phase II study | Sodium selenite | 500 or 300/day | Oral (during radiotherapy) | Side effect evaluation | Reduced the development of dysphagia due to radiotherapy |